Desperate to slow her cognitive decline, one patient shares her hopes and concerns about the first new Alzheimer’s drug in nearly 20 years.
This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.
Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter
Podden och tillhörande omslagsbild på den här sidan tillhör Tradeoffs. Innehållet i podden är skapat av Tradeoffs och inte av, eller tillsammans med, Poddtoppen.